Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD
← catalyst calendarNCT07773246 · readout ≤ 377 d
Sponsored by Korro Bio, Inc. (industry) · KRRO — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
30estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urea Cycle Disorders, Inborn
- Urea Cycle Disorders
- Ornithine Transcarbamylase (OTC) Deficiency
- Arginase 1 Deficiency
- NAGS Deficiency
- Carbamylphosphate Synthetase I
- Ornithine Transporter Mitochondrial 1
- Argininosuccinate Synthase
- Argininosuccinate Lyase Deficiency
- N-acetyl Glutamate - Synthetase
- Citrin Deficiency
Interventions
- Drug: KRRO-121
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability
measured Day 1 through 14 days post-dose
Safety and Tolerability
measured Day 1 through Day 50
Permalink · KRRO's whole pipeline · Catalyst calendar · Every registered study · What changed